{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T19:23:51Z","timestamp":1749410631114,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15K08492"],"award-info":[{"award-number":["15K08492"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12328-018-0884-y","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T07:57:27Z","timestamp":1531295847000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Three renal failure cases successfully treated with ombitasvir\/paritaprevir\/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation"],"prefix":"10.1007","volume":"12","author":[{"given":"Noriaki","family":"Orita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-4056","authenticated-orcid":false,"given":"Tetsuro","family":"Shimakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Sunagozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Horii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouki","family":"Nio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tekeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriho","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishiro","family":"Mizukoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,11]]},"reference":[{"key":"884_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/tri.12329","volume":"27","author":"N Akamatsu","year":"2014","unstructured":"Akamatsu N, Sugawara Y, Kokudo N, et al. Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int. 2014;27:767\u201374.","journal-title":"Transpl Int"},{"key":"884_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/lt.20238","volume":"10","author":"RJ Firpi","year":"2004","unstructured":"Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 2004;10:1240\u201347.","journal-title":"Liver Transpl"},{"key":"884_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825\u201332.","journal-title":"Lancet"},{"key":"884_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","volume":"49","author":"M Berenguer","year":"2008","unstructured":"Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274\u201387.","journal-title":"J Hepatol"},{"key":"884_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/jhbp.171","volume":"22","author":"T Tanaka","year":"2015","unstructured":"Tanaka T, Sugawara Y, Akamatsu N, et al. Use of simeprevir following pre-emptive pegylated interferon\/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci. 2015;22:144\u201350.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"884_CR6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1097\/TP.0000000000000166","volume":"98","author":"T Ikegami","year":"2014","unstructured":"Ikegami T, Yoshizumi T, Kato M, et al. Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Transplantation. 2014;98:994\u20139.","journal-title":"Transplantation"},{"key":"884_CR7","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"884_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1053\/j.gastro.2012.01.030","volume":"142","author":"J Levitsky","year":"2012","unstructured":"Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142:1132\u20139.e1.","journal-title":"Gastroenterology"},{"key":"884_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","volume":"148","author":"M Charlton","year":"2015","unstructured":"Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108\u201317.","journal-title":"Gastroenterology"},{"key":"884_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/hepr.12602","volume":"46","author":"T Kawaoka","year":"2016","unstructured":"Kawaoka T, Imamura M, Morio K, et al. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: case report. Hepatol Res. 2016;46:707\u201312.","journal-title":"Hepatol Res"},{"key":"884_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2017.06.006","author":"ML Yu","year":"2017","unstructured":"Yu ML, Chen YL, Huang CF, et al. Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: real-world experience. J Formos Med Assoc. 2017. \n                    https:\/\/doi.org\/10.1016\/j.jfma.2017.06.006\n                    \n                  \n                           (Epub ahead of print).","journal-title":"J Formos Med Assoc"},{"key":"884_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","volume":"371","author":"PY Kwo","year":"2014","unstructured":"Kwo PY, Mantry PS, Corakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375\u201382.","journal-title":"N Engl J Med"},{"key":"884_CR13","doi-asserted-by":"publisher","first-page":"10760","DOI":"10.3748\/wjg.v21.i38.10760","volume":"21","author":"E Righi","year":"2015","unstructured":"Righi E, Londero A, Carnelutti A, et al. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol. 2015;21:10760\u201375.","journal-title":"World J Gastroenterol"},{"key":"884_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12328-017-0722-7","volume":"10","author":"T Kawaoka","year":"2017","unstructured":"Kawaoka T, Imamura M, Morio K, et al. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. Clin J Gastroenterol. 2017;10:179\u201384.","journal-title":"Clin J Gastroenterol"},{"key":"884_CR15","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"884_CR16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"H Kumada","year":"2015","unstructured":"Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037\u201346.","journal-title":"Hepatology"},{"issue":"44","key":"884_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/hepr.12272","volume":"2014","author":"Drafting Committee for Hepatitis Management Guidelines","year":"2014","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: a 2014 update for Genotype 1. Hepatol Res. 2014;44:59\u201370.","journal-title":"Hepatol Res."},{"key":"884_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. Hepatology. 2017;66:153\u201394.","journal-title":"Hepatology"},{"key":"884_CR19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","unstructured":"AASLD\/IDSA HCV Guidance Panel. Hepatitis C guideline: AASLD and IDSA guidelines. Recommendations for testing, managing, and treating hepatitis C. Hepatology. 2015;62:932\u201354.","journal-title":"Hepatology"},{"key":"884_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda G, Furusyo N, Toyoda H, et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol. 2018;53:119\u201328. \n                    https:\/\/doi.org\/10.1007\/s00535-017-1353-y\n                    \n                  \n                           (Epub 2017 May 30).","journal-title":"J Gastroenterol"},{"key":"884_CR21","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/hepr.12910","volume":"47","author":"M Atsukawa","year":"2017","unstructured":"Atsukawa M, Tsubota A, Koushima Y, et al. Efficacy and safety of ombitasvir\/paritaprevir\/ ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res. 2017;47:1429\u201337.","journal-title":"Hepatol Res"},{"key":"884_CR22","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/ajt.13111","volume":"15","author":"P Badri","year":"2015","unstructured":"Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015;15:1313\u201322.","journal-title":"Am J Transplant"},{"key":"884_CR23","unstructured":"VIEKIRA PAK Highlights of Prescribing Information FDA. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206619lbl.pdf\n                    \n                  . Accessed 29 Mar 2018."},{"key":"884_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/lt.23566","volume":"19","author":"MR Lucey","year":"2013","unstructured":"Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplant. 2013;19:3\u201326.","journal-title":"Liver Transplant"},{"key":"884_CR25","unstructured":"GLE\/PIB Highlights of Prescribing Information. FDA. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209394s000lbl.pdf\n                    \n                  . Accessed 29 Mar 2018."},{"key":"884_CR26","unstructured":"EBV plus GZR Highlights of Prescribing Information. FDA. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208261s002lbl.pdf\n                    \n                  . Accessed 29 Mar 2018."}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-018-0884-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-018-0884-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-018-0884-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T10:03:05Z","timestamp":1589450585000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-018-0884-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s12328-018-0884-y","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2018,7,11]]},"assertion":[{"value":"16 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}